GoAI
Get started
ENvue Medical, Inc. logo

ENvue Medical, Inc.

FEED

NASDAQHealthcareMedical - Specialties

Open in GoAI

Previous close

$0.3906

−$0.0112 · -2.79%

Aug 21, 4:00 PM ET

FEED company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

21

Expensive

Momentum

23

Weakening

Sentiment

47

Mixed

Risk resilience

23

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

NanoVibronix, Inc. focuses on developing non-surgical medical devices that stimulate biological responses. Its core offerings include UroShield and PainShield. The company's business activities span across several global markets, such as the United States, Europe, Australia, India, and Israel, in addition to other territories. This enterprise was founded by Harold Jacob and Jona Zumeris in September 2003, and its main corporate office is situated in Tyler, Texas.

Industry
Medical - Specialties
Sector
Healthcare
Headquarters
US
CEO
Doron Robert Besser
Listed since
Dec 12, 2025
Employees
13

Market position

Day range

Current $0.3906

52-week range

Current $0.3906

Open
$0.4041
Previous close
$0.4018
Volume
50.81K
0.05× average
Average volume
1.03M
Average daily volume
Market cap
3.63M USD
Beta
1.56
Market reference 1
50-day average
$4.00
-90.23% below average
200-day average
$4.00
-90.23% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
-1.04M USD
P/E (TTM)
-0×
P/B (TTM)
0.08×
P/S (TTM)
1.89×
EV / EBITDA
0.06×
Earnings yield
-917.05%
Free cash flow yield
-475.65%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-26.06%
Operating margin
-783.59%
Net margin
-1088.94%
Return on equity
-54.29%
Return on assets
-44.22%
Return on invested capital
-32.39%

Financial health

Debt / equity
0.04×
Current ratio
1.09×
Altman Z-score
-5.6
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends158%-206%-570%-934%Gross margin, FY2021: 45.43%Gross margin, FY2022: 22.21%Gross margin, FY2023: 67.32%Gross margin, FY2024: 58.95%Gross margin, FY2025: 5.99%Operating margin, FY2021: -335.28%Operating margin, FY2022: -666.49%Operating margin, FY2023: -150.50%Operating margin, FY2024: -140.03%Operating margin, FY2025: -459.66%Net margin, FY2021: -842.60%Net margin, FY2022: -724.47%Net margin, FY2023: -162.55%Net margin, FY2024: -144.84%Net margin, FY2025: -712.30%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 45.43%. Gross margin FY2022 22.21%. Gross margin FY2023 67.32%. Gross margin FY2024 58.95%. Gross margin FY2025 5.99%. Operating margin FY2021 -335.28%. Operating margin FY2022 -666.49%. Operating margin FY2023 -150.50%. Operating margin FY2024 -140.03%. Operating margin FY2025 -459.66%. Net margin FY2021 -842.60%. Net margin FY2022 -724.47%. Net margin FY2023 -162.55%. Net margin FY2024 -144.84%. Net margin FY2025 -712.30%.

Income trends

Revenue

2.55M USD-0.20%

Operating income

−11.74M USD-227.61%

Net income

−18.19M USD-390.82%
Income trends across reported periods4.63M USD−3.66M USD−11.96M USD−20.26M USDRevenue, FY2021: 1.7M USDRevenue, FY2022: 752K USDRevenue, FY2023: 2.28M USDRevenue, FY2024: 2.56M USDRevenue, FY2025: 2.55M USDOperating income, FY2021: −5.68M USDOperating income, FY2022: −5.01M USDOperating income, FY2023: −3.44M USDOperating income, FY2024: −3.58M USDOperating income, FY2025: −11.74M USDNet income, FY2021: −14.28M USDNet income, FY2022: −5.45M USDNet income, FY2023: −3.71M USDNet income, FY2024: −3.71M USDNet income, FY2025: −18.19M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.7M USD. Revenue FY2022 752K USD. Revenue FY2023 2.28M USD. Revenue FY2024 2.56M USD. Revenue FY2025 2.55M USD. Operating income FY2021 −5.68M USD. Operating income FY2022 −5.01M USD. Operating income FY2023 −3.44M USD. Operating income FY2024 −3.58M USD. Operating income FY2025 −11.74M USD. Net income FY2021 −14.28M USD. Net income FY2022 −5.45M USD. Net income FY2023 −3.71M USD. Net income FY2024 −3.71M USD. Net income FY2025 −18.19M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue2.55M USD2.56M USD2.28M USD752K USD1.7M USD
Cost of goods sold2.4M USD1.05M USD746K USD585K USD925K USD
Gross profit153K USD1.51M USD1.54M USD167K USD770K USD
Research and development1.76M USD909K USD185K USD283K USD293K USD
Selling, general, and administrative10.13M USD4.18M USD4.79M USD4.9M USD6.16M USD
Operating expenses11.89M USD5.09M USD4.97M USD5.18M USD6.45M USD
Interest expense288K USD135K USD246K USD347K USD—
Depreciation and amortization897K USD1K USD1K USD1K USD2K USD
Operating income−11.74M USD−3.58M USD−3.44M USD−5.01M USD−5.68M USD
Net income−18.19M USD−3.71M USD−3.71M USD−5.45M USD−14.28M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-19.54
FY2025
Latest fiscal-year revenue
2.55M USD
FY2025 · -0.20% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend103.37-388.28-879.94-1,371.59FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend2.74M2.02M1.29M571.4KFY21FY22FY23FY24FY25

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$4.65

1090.48% upside
Past 12 months12-month forecast

Price history unavailable

High $4.65Average $4.65Low $4.65

FEED news

globenewswire.com

ENvue Medical Announces Exclusive UroShield® Distribution Agreement with Minimum Purchase Commitments of Approximately $2.6 Million

Multi-year agreement with Peak Medical expands UroShield commercialization across the United Kingdom and Republic of Ireland Multi-year agreement with Peak Medical expands UroShield commercialization across the United…

Read source
globenewswire.com

ENvue Medical Secures Equity Financing Facility of Up to $50 Million to Support Commercial Growth, Technology Expansion and Strategic Acquisitions

TYLER, Texas, Aug. 12, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) ("ENvue" or the "Company"), a commercial-stage medical technology company, today announced that it has entered into a securities purchase…

Read source
globenewswire.com

ENvue Medical Moves NanoVibronix Manufacturing to the United States, Consolidates R&D in Tel Aviv, Israel, Increasing Operational Efficiencies and Cost Reduction Opportunities

TYLER, Texas, Aug. 04, 2026 (GLOBE NEWSWIRE) -- ENvue Medical , Inc. (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company, today announced it has completed the transition of its…

Read source
globenewswire.com

ENvue Medical Deploys Additional Navigation Platform with Existing Customer, A Leading North Texas Medical Center

Additional Platform Deployment at Major Academic Medical Center Reflects Increasing Commercial Demand for Bedside Feeding Tube Navigation Additional Platform Deployment at Major Academic Medical Center Reflects…

Read source
globenewswire.com

ENvue Medical Appoints Chairman of the Board and New Directors, Bringing Clinical, AI Governance and Capital Markets Expertise to Navigation Platform

Zeev Rotstein, M.D. Named Chairman Following Four Decades in Health System Leadership, Including 12 Years as Director General of Sheba Medical Center Zvi Joseph and Lior Buchman Join Board, Bringing Amdocs AI Governance…

Read source
benzinga.com

Envue Medical Expands AI Navigation Platform With Robotic Prototype

ENvue Medical, Inc. (NASDAQ:FEED) announced Thursday the development and demonstration of the prototype of ENvue Drive.

Read source

FEED peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding FEED

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
59.65
Weight
—
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research FEED

research.disclaimer